Business · 23/04/2025Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to Sponsor of Material Threat MCM Product
Summary
The FDA has awarded a priority review voucher to Ridgeback Biotherapeutics, LP, the sponsor of EBANGA (ansuvimab-zykl) for injection, a material threat medical countermeasure product approved on December 21, 2020.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →